COMPANY RESEARCHNovartis is a Switzerland-based innovative medicines company active in the discovery, development, manufacture and commercialization of prescription treatments. Its official therapeutic-area pages identify cardiovascular, renal and metabolic conditions, immunology, neuroscience and oncology as major areas of focus. It employs multiple therapeutic technologies rather than a single drug-development platform. Official investor materials list ordinary shares on SIX Swiss Exchange under NOVN and American depositary receipts on the New York Stock Exchange under NVS.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Novartis is a Switzerland-based innovative medicines company active in the discovery, development, manufacture and commercialization of prescription treatments. Its official therapeutic-area pages identify cardiovascular, renal and metabolic conditions, immunology, neuroscience and oncology as major areas of focus. It employs multiple therapeutic technologies rather than a single drug-development platform. Official investor materials list ordinary shares on SIX Swiss Exchange under NOVN and American depositary receipts on the New York Stock Exchange under NVS.
SIX: NOVN NYSE: NVS
small-molecule · biologics · radioligand-therapy
oncology · immunology · neuroscience · cardiometabolic
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
NEORAL cyclosporine is a classic benchmark for oral cyclic peptides and microemulsion preconcentrates; it should not be assumed bioequivalent to Sandimmune.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| cyclosporine / NEORAL | Cyclophilin / Calcineurin · Immunosuppression-related indications | Approved | Label reports systemic exposure and formulation differences |
| DKY709 | IKZF2 / Helios · See individual trial / indication; not individually confirmed in this review | Phase 1 | Human target degradation and preliminary safety / efficacy |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 2 / 2 related items
Monte Rosa announced that Novartis initiated a second Phase 2 study of the VAV1 molecular glue degrader MRT-6160, also called DDY391, in active moderate to severe psoriatic arthritis. The randomized, double-blind, placebo-controlled trial will assess efficacy, safety, tolerability, and dose response. The first patient visit triggers a $37.5 million milestone payment.
Unnatural Products licensed an undisclosed cardiovascular program to Novartis. Terms include up to $100 million in upfront and pre-IND payments, plus up to $1.7 billion in later milestones and royalties. The platform supports oral and injectable macrocycles; the announcement does not establish the specific program’s route or imply all contingent payments have been received.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.